利妥昔单抗联合来那度胺六个月方案治疗晚期初治滤泡性淋巴瘤:SAKK 35/10 试验 10 年更新
SAKK 35/10 随机 2 期试验比较利妥昔单抗单药与利妥昔单抗联合来那度胺用于需要全身治疗的 1-3A 级滤泡性淋巴瘤初治患者,两组各 77 例。中位随访 9.5 年后,联合组在缓解持续时间、无进展生存和至下次治疗时间上均优于单药组,总生存两组相似,联合组毒性更常见但可控。
要点
- 联合组中位缓解持续时间未达到 vs 单药组 3.2 年(HR 0.42,95%CI 0.21-0.86,P=.014)。
- 联合组中位无进展生存 9.3 年 vs 单药组 2.3 年(HR 0.57,95%CI 0.37-0.89,P=.0128)。
- 10 年总生存两组相似(联合组 77% vs 单药组 78%,P=.881),联合组毒性更常见但可控。
核心结论
- SAKK 35/10 试验长期结果证实,短期无化疗的利妥昔单抗联合来那度胺一线方案对有症状滤泡性淋巴瘤具有持久获益。
研究设计与样本
- 瑞士临床癌症研究组(SAKK)与北欧淋巴瘤组开展的随机 2 期试验,比较利妥昔单抗单药与利妥昔单抗联合来那度胺作为滤泡性淋巴瘤初始治疗。
- 纳入需要全身治疗的 1-3A 级滤泡性淋巴瘤患者,随机分为利妥昔单抗组(n=77;375 mg/m2 静脉注射×1,第 1-4 周)和利妥昔单抗-来那度胺组(n=77;利妥昔单抗同方案,来那度胺 15 mg 每日连续给药)。
- 第 10 周评估有效者于第 12-15 周重复利妥昔单抗,联合或不联合来那度胺(共 18 周)。
- 两组均有 47% 患者滤泡性淋巴瘤国际预后指数(FLIPI)评分为不良风险。
主要发现
- 中位随访 9.5 年后,联合组中位缓解持续时间未达到 vs 单药组 3.2 年(HR 0.42,95%CI 0.21-0.86,P=.014)。
- 联合组中位无进展生存 9.3 年 vs 单药组 2.3 年(HR 0.57,95%CI 0.37-0.89,P=.0128)。
- 联合组中位至下次治疗时间未达到 vs 单药组 2.1 年(HR 0.43,95%CI 0.27-0.67,P<.001)。
- 超过 60% 的联合组有效者在 10 年时仍处于首次完全缓解。
- 10 年总生存两组相似(联合组 77% vs 单药组 78%,P=.881);联合组毒性更常见但可控。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group conducted the SAKK 35/10 randomized phase 2 trial to compare rituximab (R) alone vs R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL). Patients with grade 1 to 3A FL, requiring systemic therapy, were randomized to either R (n = 77; 375 mg/m2 IV × 1, weeks 1-4) or rituximab-lenalidomide (RL) (n = 77; R on the same schedule and L at 15 mg daily continuously). Responders (evaluated at 10 weeks) repeated R during weeks 12 to 15 with or without L (for a total of 18 weeks). Both arms had 47% of patients with a poor risk score on the FL International Prognostic Index. The primary end point, complete response (CR)/CR unconfirmed rates at 6 months, was superior with the combination, and after a median follow-up of 9.5 years, this has translated into a longer duration of response (median, not reached vs 3.2 years; hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.21-0.86; P = .014), progression-free survival (9.3 vs 2.3 years; HR, 0.57; 95% CI: 0.37-0.89; P = .0128), and time to next treatment (median, not reached vs 2.1 years; HR, 0.43; 95% CI, 0.27-0.67; P < .001). Over 60% of RL responders remained in first CR at 10 years. Overall survival was similar in both arms (77% vs 78% at 10 years; P = .881). Toxicity was more common with RL but manageable. The SAKK 35/10 trial's long-term results confirmed a durable benefit of a short-term chemotherapy-free first-line RL regimen in symptomatic FL. This trial was registered at www.clinicaltrials.gov as #NCT0137605.
引用
- Kimby E, Schär S, Pirosa MC, et al. Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update. Blood Adv. 2025. PMID: 39883948. doi:10.1182/bloodadvances.2024014840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。